Dr. med. Dennis Kannenkeril

Oberarzt, Internist, Facharzt für Innere Medizin und Nephrologie, Hypertensiologe (DHL), ESH Clinical Hypertension Specialist

Einrichtungen
Medizin 4
Transplantationszentrum

dennis.kannenkeril(at)uk-erlangen.de

Lebenslauf, Veröffentlichungen und Auszeichnungen

Publikationen

Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, Bramlage P, Nöh L, Schiffer M, Uder M, Achenbach S, Schmieder RE: (2023) The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial. Clin Res Cardiol. 2023;112(1): 134-144
Pietschner R, Bosch A, Kannenkeril D, Striepe K, Schiffer M, Achenbach S, Schmieder RE, Kolwelter J: (2023) Is vascular remodelling in patients with chronic heart failure exaggerated? ESC Heart Fail. 2023;10(1): 245-254
Bosch A, Poglitsch M, Kannenkeril D, Kolwelter J, Striepe K, Ott C, Rauh M, Schiffer M, Achenbach S, Schmieder RE: (2023) Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure. ESC Heart Fail. 2023;10(3): 1635-1642
Bosch A, Kannenkeril D, Jung S, Striepe K, Karg MV, Ott C, Schmieder RE: (2022) The influence of aircraft noise exposure on the systemic and renal haemodynamics. Eur J Prev Cardiol. 2022;29(1): 116-124
Kannenkeril D, Nolde JM, Kiuchi MG, Carnagarin R, Lugo-Gavidia LM, Chan J, Joyson A, Jose A, Robinson S, Matthews VB, Herat LY, Azzam O, Frost S, Schlaich MP: (2022) Retinal Capillary Damage Is Already Evident in Patients With Hypertension and Prediabetes and Associated With HbA1c Levels in the Nondiabetic Range. Diabetes Care. 2022;45(6): 1472-1475
Kolwelter J, Striepe K, Bosch A, Kannenkeril D, Ott C, Schiffer M, Schmieder RE: (2022) Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study. Diabetol Metab Syndr. 2022;14(1):
Kannenkeril D, Bosch A, Striepe K, Berner L, Pietschner R, Kolwelter J, Ott C, Schiffer M, Achenbach S, Schmieder RE: (2022) Evolocumab Alters Vascular Function in Patients With Cardiovascular Disease Circulation. 2022;146 Suppl 1():
Bosch A, Poglitsch M, Kannenkeril D, Ott C, Pietschner R, Striepe K, Schiffer M, Schmieder RE: (2022) ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE J Hypertens. 2022;40 Suppl 1(SUPPL 1): E283-E284
Kannenkeril D, Ott C, Bosch A, Striepe K, Pietschner R, Schiffer M, Schmieder RE: (2022) IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES J Hypertens. 2022;40 Suppl 1(SUPPL): E59-E59
Kannenkeril D, Kolwelter J, Pietschner R, Striepe K, Bosch A, Achenbach S, Schmieder RE: (2022) SEMI-AUTOMATIC MEASUREMENT OF INTIMA-MEDIA THICKNESS OF BRACHIAL ARTERY IN PATIENTS WITH CONGESTIVE HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL): E239-E239
Kannenkeril D, Kolwelter J, Pietschner R, Striepe K, Bosch A, Achenbach S, Schmieder RE: (2022) SEMI-AUTOMATIC MEASUREMENT OF INTIMA-MEDIA THICKNESS OF BRACHIAL ARTERY IN PATIENTS WITH CONGESTIVE HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL): E239-E239
Kannenkeril D, Ott C, Bosch A, Striepe K, Pietschner R, Schiffer M, Schmieder RE: (2022) IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES J Hypertens. 2022;40 Suppl 1(SUPPL): E59-E59
Pietschner R, Kolwelter J, Bosch A, Striepe K, Kannenkeril D, Ott C, Schiffer M, Achenbach S, Schmieder RE: (2022) DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL 1): E129-E129
Pietschner R, Kolwelter J, Bosch A, Striepe K, Kannenkeril D, Ott C, Schiffer M, Achenbach S, Schmieder RE: (2022) DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE J Hypertens. 2022;40 Suppl 1(SUPPL): E129-E129
Gessner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm MF, Schmieder RE, Maas R: (2022) Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers. Cardiovasc Diabetol. 2022;21(1):
Nolde JM, Lugo-Gavidia LM, Kannenkeril D, Chan J, Robinson S, Jose A, Joyson A, Schlaich L, Carnagarin R, Azzam O, Kiuchi MG, Schlaich MP: (2022) Simultaneously measured inter-arm blood pressure difference is not associated with pulse wave velocity in a clinical dataset of at-risk hypertensive patients. J Hum Hypertens. 2022;36(9): 811-818
Kannenkeril D, Frost S, Nolde JM, Kiuchi MG, Carnagarin R, Lugo-Gavidia LM, Chan J, Joyson A, Matthews VB, Herat LY, Azzam O, Mehdizadeh M, Vignarajan J, Kanagasingam Y, Schlaich MP: (2021) Microvascular changes at different stages of chronic kidney disease. J Clin Hypertens (Greenwich). 2021;23(2): 309-316
Nolde JM, Kiuchi MG, Carnagarin R, Frost S, Kannenkeril D, Lugo-Gavidia LM, Chan J, Joyson A, Matthews VB, Herat LY, Azzam O, Schlaich MP: (2021) Supine blood pressure-A clinically relevant determinant of vascular target organ damage in hypertensive patients. J Clin Hypertens (Greenwich). 2021;23(1): 44-52
Jung S, Bosch A, Kolwelter J, Striepe K, Kannenkeril D, Schuster T, Ott C, Achenbach S, Schmieder RE: (2021) Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2021;8(2): 1562-1570
Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Bramlage P, Schiffer M, Schmieder RE: (2021) Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. Cardiovasc Diabetol. 2021;20(1):
Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder RE: (2021) Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Fail. 2021;8(6): 5327-5337
Kannenkeril D, Jung S, Ott C, Striepe K, Kolwelter J, Schmieder RE, Bosch A: (2021) Association of Noise Annoyance with Measured Renal Hemodynamic Changes. Kidney Blood Press Res. 2021;46(3): 323-330
Kannenkeril D, Jung S, Harazny J, Striepe K, Ott C, Dahlmann A, Kopp C, Schiffer M, Linz P, Nagel AM, Uder M, Schmieder RE: (2021) Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. J Diabetes Complications. 2021;35(12):
Nolde JM, Frost S, Kannenkeril D, Lugo-Gavidia LM, Chan J, Joyson A, Azzam O, Carnagarin R, Kiuchi MG, Vignarajan J, Schlaich MP: (2021) Capillary vascular density in the retina of hypertensive patients is associated with a non-dipping pattern independent of mean ambulatory blood pressure. J Hypertens. 2021;39(9): 1826-1834
Nolde JM, Lugo-Gavidia LM, Kannenkeril D, Chan J, Matthews VB, Carnagarin R, Azzam O, Kiuchi MG, Schlaich MP: (2021) Increased pulse wave velocity in patients with an orthostatic blood pressure rise independent of other cardiovascular risk factors. J Hypertens. 2021;39(7): 1352-1360
Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, Ott C, Schiffer M, Achenbach S, Schmieder RE: (2021) Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol. 2021;20(1):
Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, Bramlage P, Uder M, Achenbach S, Schmieder RE: (2021) Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin Eur Heart J. 2021;42 Suppl 1(): 795-795
Pietschner R, Kolwelter J, Bosch A, Kannenkeril D, Ott C, Schiffer M, Achenbach S, Schmieder RE: (2021) Effect of SGLT2 inhibition on ketone bodies in patients with stable chronic heart failure Diabetologia. 2021;64 Suppl 1(SUPPL 1): 107-107
Bosch A, Poglitsch M, Kannenkeril D, Ott C, Striepe K, Schmieder RE: (2021) Angiotensin profiles in patients with type 2 diabetes and combination therapy of empagliflozin and linagliptin versus metformin and insulin glargine Diabetologia. 2021;64 Suppl 1(SUPPL 1): 256-256
Kannenkeril D, Janka R, Bosch A, Jung S, Kolwelter J, Striepe K, Ott C, Martirosian P, Schiffer M, Uder M, Schmieder RE: (2021) Detection of Changes in Renal Blood Flow Using Arterial Spin Labeling MRI. Am J Nephrol. 2021;52(1): 69-75
Kannenkeril D, Bosch A, Kolwelter J, Jung S, Striepe K, Ott C, Delles C, Schmieder RE: (2021) Dependency of flow-mediated vasodilatation from basal nitric oxide activity. Clin Physiol Funct Imaging. 2021;41(4): 310-316
Lugo-Gavidia LM, Burger D, Matthews VB, Nolde JM, Galindo Kiuchi M, Carnagarin R, Kannenkeril D, Chan J, Joyson A, Herat LY, Azzam O, Schlaich MP: (2021) Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation. Hypertension. 2021;77(6): 1825-1844
Bosch A, Kannenkeril D, Rauh M, Ott C, Striepe K, Jung S, Kolwelter J, Schmieder RE: (2021) RELATION BETWEEN NOISE ANNOYANCE, STRESS HORMONES AND THE RENAL HEMODYNAMIC J Hypertens. 2021;39 Suppl 1(): E178-E178
Bosch A, Kannenkeril D, Ott C, Harazny JM, Striepe K, Karg MV, Jung S, Kolwelter J, Schmieder RE: (2021) ANNOYANCE DUE TO NOISE TRIGGERS VASCULAR CHANGES IN THE RENAL HEMODYNAMIC J Hypertens. 2021;39 Suppl 1(): E169-E169
Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Ott C, Schiffer M, Schmieder RE: (2021) LOW DOSE-EPLERENONE TREATMENT DECREASES AORTIC STIFFNESS IN PATIENTS WITH METABOLIC SYNDROME J Hypertens. 2021;39 Suppl 1(): E338-E338
Kannenkeril D, Janka R, Bosch A, Jung S, Kolwelter J, Striepe K, Ott C, Martirosian P, Schiffer M, Uder M, Schmieder RE: (2021) DETECTION OF CHANGES IN RENAL BLOOD FLOW USING ARTERIAL SPIN LABELING MRI J Hypertens. 2021;39 Suppl 1(): E307-E307
Kolwelter J, Striepe K, Kannenkeril D, Jung S, Bosch A, Ott C, Schmieder RE: (2021) CAN WE IDENTIFY GLOMERULAR HYPERFILTRATION IN PATIENTS WITH TYPE 2 DIABETES BY CLINICAL PARAMETERS? J Hypertens. 2021;39 Suppl 1(): E211-E211
Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, Bramlage P, Uder M, Achenbach S, Schmieder R: (2021) THE SGLT2 INHIBITOR EMPAGLIFLOZIN REDUCES TISSUE SODIUM CONTENT IN PATIENTS WITH CHRONIC HEART FAILURE J Am Coll Cardiol. 2021;77 Suppl 1(18): 585-585
Kolwelter J, Bosch A, Jung S, Linz P, Kannenkeril D, Nagel AM, Ott C, Bramlage P, Uder M, Achenbach S, Schmieder R: (2021) EFFECTS OF THE SGLT2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE J Am Coll Cardiol. 2021;77 Suppl 1(18): 1806-1806
Dobbie LJ, Mackin ST, Hogarth K, Lonergan F, Kannenkeril D, Brooksbank K, Delles C: (2020) Validation of semi-automated flow-mediated dilation measurement in healthy volunteers. Blood Press Monit. 2020;25(4): 216-223
Jung S, Bosch A, Kannenkeril D, Karg MV, Striepe K, Bramlage P, Ott C, Schmieder RE: (2020) Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2020;6(6): 364-371
Jung S, Bosch A, Ott C, Kannenkeril D, Dienemann T, Harazny JM, Michelson G, Schmieder RE: (2020) Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography. Sci Rep. 2020;10(1):
Bosch A, Schmid A, Ott C, Kannenkeril D, Karg M, Ditting T, Veelken R, Uder M, Schmieder RE: (2020) Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation. Am J Hypertens. 2020;33(2): 182-189
Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C, Lee DP, Ma A, Ewen S, Cohen DL, Wilensky R, Devireddy CM, Lea J, Schmid A, Weil J, Agdirlioglu T, Reedus D, Jefferson BK, Reyes D, D'Souza R, Sharp ASP, Sharif F, Fahy M, DeBruin V, Cohen SA, Brar S, Townsend RR, SPYRAL HTN-OFF MED Pivotal Investigators , Akarca E, Allaqaband S, Andrikou E, Aoki J, Arnold A, Aronow H, Asami M, Bachinsky W, Barton J, Bass K, Batson B, Bell C, Bertolet B, Bewarder Y, Bihlmaier K, Binner C, Bloom J, Blossom B, Brar S, Brown A, Burke R, Burke MN, Butler M, Calhoun W, Campbell J, Carroll S, Chapman N, Chasen C, Cheng SC, Chia B, Choksi N, Cohen J, Connolly N, Contreras J, Cusack R, Dangas G, David S, Davies J, Dederer J, Denker M, Desch U, Didangelos M, Dienemann T, Dimitriadis K, Dorval JF, Estess J, Fan S, Fengler K, Ferguson L, Fudim M, Fuster V, Garcia F, Garcia S, Garton A, Gessler C, Ghali M, Gummadi B, Gupta A, Gutierrez A, Hardesty P, Hartung P, Haught WH, Haun Y, Hays S, Helmreich W, Hill D, Hopper I, Horiuchi Y, Hoshide S, Howard J, Ikeda W, Jan F, Jauhar R, Jay D, Johnson J, Johnston T, Jones S, Jung S, Kalos T, Kanitkar M, Kannenkeril D, Kasiakogias A, Kazziha S, Keene D, Khitha J, Kikushima H, Kobayashi T, Komiyama K, Komori T, Kotter J, Kouparanis A, Krasnow J, Kulenthiran S, Kumar S, L'Allier P, Laney P, Lauder L, Lavoie MA, Lerche M, Linesky E, Little N, Lomboy C, Lucic J, Lurz P, Lynch S, Mansukhani P, McDuffie K, McGrath B, McLaurin B, Meade A, Meraj P, Millenaar D, Moore N, Mori F, Munch P, Murphy J, Murray J, Nanjundappa A, Ninomiya K, Oba Y, O'Connor T, Ogata Y, Ogoyama Y, Onsrud R, Ott C, Padaliya B, Pagidipati N, Patel M, Patel K, Petteinidou E, Porr W, Rao A, Razi R, Regan C, Remetz M, Rizik D, Robison M, Rommel KP, Rosseel L, Rothstein M, Rough R, Saavedra J, Saba S, Schwartz R, Selcer S, Sen S, Sennott J, Shadman R, Shah S, Shemin D, Shimizu H, Shimpo M, Shishehbor M, Shun-Shin M, Sierra F, Singh J, Singh A, Sirajeldin Y, Skeik N, Soliman G, Statton S, Stehli J, Steigerwalt S, Striepe K, Stuck J, Suppan M, Svetkey L, Takker G, Tanabe K, Tanaka T, Tomii D, Torre S, Traverse J, Tyson C, Vasquez A, Velasquez E, Vemulapalli S, Waki H, Walton T, Wang Y, Weber T, Wells B, Wilkins R, Wright T, Yahagi K, Yeung A, Zadegan R, Zeller T, Ziada K, Ziakas A, Zidar D: (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234): 1444-1451
Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, Dienemann T, Schmieder RE: (2019) How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. Cardiovasc Diabetol. 2019;18(1):
Kannenkeril D, Karg MV, Bosch A, Ott C, Linz P, Nagel AM, Uder M, Schmieder RE: (2019) Tissue sodium content in patients with type 2 diabetes mellitus. J Diabetes Complications. 2019;33(7): 485-489
Jung S, Bosch A, Kohler N, Ott C, Kannenkeril D, Dienemann T, Harazny JM, Michelson G, Schmieder RE: (2019) Evidence of neurodegeneration in individuals with only mildly elevated blood pressure. J Hypertens. 2019;37(12): 2389-2397
Kannenkeril D, Bosch A, Harazny J, Karg M, Jung S, Ott C, Schmieder RE: (2018) Early vascular parameters in the micro- and macrocirculation in type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):
Bosch A, Kannenkeril D, Ott C, Harazny JM, Striepe K, Karg M, Dienemann T, Jung S, Schmieder RE: (2018) THE INFLUENCE OF ANNOYANCE DUE TO NOISE ON RENAL HEMODYNAMIC J Hypertens. 2018;36(): E39-E39
Bosch A, Ott C, Kannenkeril D, Harazny JM, Striepe K, Karg M, Dienemann T, Jung S, Schmieder RE: (2018) DIFFERENT RESPONSE PATTERN TO AIRCRAFT NOISE EXPOSURE IN RENAL VERSUS SYSTEMIC HEMODYNAMIC J Hypertens. 2018;36(): E138-E138
Bosch A, Ott C, Schmid A, Kannenkeril D, Karg M, Ditting T, Veelken R, Uder M, Schmieder RE: (2018) COPEPTIN AS A RESEARCH MARKER IN CARDIOVASCULAR DISEASE J Hypertens. 2018;36(): E35-E35
Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, Dienemann T, Schmieder RE: (2018) How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Eur Heart J. 2018;39(): 869-869
Kannenkeril D, Karg M, Bosch A, Ott C, Harazny J, Schmieder RE: (2018) EARLY VASCULAR PARAMETERS IN THE MICRO- AND MACROCIRCULATION IN TYPE 2 DIABETES J Hypertens. 2018;36(): E9-E9
Kannenkeril D, Harazny JM, Bosch A, Ott C, Michelson G, Schmieder RE, Friedrich S: (2018) Retinal vascular resistance in arterial hypertension. Blood Press. 2018;27(2): 82-87
Karg MV, Bosch A, Kannenkeril D, Striepe K, Ott C, Schneider MP, Boemke-Zelch F, Linz P, Nagel AM, Titze J, Uder M, Schmieder RE: (2018) SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol. 2018;17(1): 5
Striepe K, Jumar A, Ott C, Karg MV, Schneider MP, Kannenkeril D, Schmieder RE: (2017) Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus. Circulation. 2017;136(12): 1167-1169
Brakemeier S, Kannenkeril D, Dürr M, Braun T, Bachmann F, Schmidt D, Wiesener M, Budde K: (2016) Experience with belatacept rescue therapy in kidney transplant recipients. Transpl Int. 2016;29(11): 1184-1195

Sprechstunden

Bluthochdruck (schwer einstellbar)

Spezialsprechstunde

Dr. med. Dennis Kannenkeril
Prof. Dr. med. Karl F. Hilgers

Zeiten
Montags ab 11 Uhr nur nach Vereinbarung

Internistisches Zentrum (INZ)
Ulmenweg 18
91054 Erlangen

Raum
D 0 723-1

Kontakt für Terminvergabe
Terminvergabe nur nach Absprache

siehe "Hinweis"

Hinweis

In dieser Sprechstunde werden Patienten mit schwer einstellbarer arterieller Hypertonie und sekundären Formen der Hypertonie behandelt.

Für diese Sprechstunde ist eine vorherige Terminvereinbarung notwendig.

Wir bitten Sie, Ihren betreuenden Hausarzt oder Internisten, uns vorab folgende Unterlagen (soweit indiziert bzw. erhoben) per Fax (an 09131 85-33431) oder per Post zu schicken:

Überweisungsschein vom Facharzt für Nephrologie
ggf. Überweisungsschein für Institut für Toxikologie Frankfurt (Urinscreening auf antihypertensive Substanzen)
Medikamentenplan
Blutwerte/Urinuntersuchung
- Blutbild
- Kalium, Natrium, Chlorid, Kreatinin, Harnstoff, Harnsäure, nüchtern bestimmte Blutfettwerte, nüchtern bestimmte Glucose
- TSH basal
- Aldosteron, Renin
- Urin-Albumin/Kreatinin-Verhältnis
Ruhe-EKG
24h-Langzeit-Blutdruckmessung
bisher vorliegende internistische Arztbriefe von ambulanten Vorstellungen/stationären Aufenthalten

Bitte denken Sie daran, Ihre Kontaktdaten bzw. die des Patienten anzugeben (Name, Adresse, Telefonnummer).

Diese Unterlagen werden dem zuständigen Oberarzt vorgelegt. Erst danach werden Sie zur Terminvereinbarung von uns angerufen oder angeschrieben.

Mitzubringen

Versicherungsnachweis (Krankenkassenkarte)

zur Kontaktliste

Schriftgröße anpassen

Dr. med. Dennis Kannenkeril